



Press release

CombinatoRx lists on NASDAQ

Munich/Zug, 10 November 2005 - *Global Life Science Ventures (GLSV)* today announced the completion of an initial public offering by CombinatoRx, one of its portfolio companies. Trading on NASDAQ began on Wednesday, November 9, 2005 under the symbol "CRXX". 6 million shares of the company's common stock were priced at \$7.00 per share, before underwriting discounts and commissions, with an option to underwriters to purchase an additional 900.000 shares. The IPO raised CombinatoRx's market capitalization to \$162 million. SG Cowen & Co., LLC acted as sole book-running manager, Pacific Growth Equities, LLC acted as co-lead manager, and Lazard Capital Markets and A.G. Edwards acted as co-managers for the offering.

CombinatoRx is a Boston-based biopharmaceutical company focused on developing new medicines that are built from synergistic combinations of approved drugs and that are designed to attack diseases on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immuno-inflammatory disease, oncology, and metabolic, neurodegenerative and infectious diseases. It has already discovered and advanced into clinical trials a portfolio of seven product candidates targeting several different diseases. Last month, CombinatoRx signed an important agreement with Angiotech Pharmaceuticals for the evaluation and exclusive licensing of CombinatoRx compounds by Angiotech in the field of drug devices and interventional medicine products.

Dr. Hans A. Küpper, Partner at GLSV and an observer on CombinatoRx's board, commented: "CombinatoRx is unique among biotech companies in its systemic approach of screening drug combinations for novel and unforeseen effects. Such a platform is very much in line with our philosophy of supporting innovative approaches to disease treatment. The success of the IPO (up 12.1% on the first day of trading) shows once again that the markets as well reward innovative companies with strong, product-focused programs."

Hanns-Peter Wiese, Partner at GLSV, added: "The IPO of CombinatoRx further validates our investment strategy, which has recently produced a series of exits for GLSV. The last 12 months have been outstanding, with four IPO's and one trade sale out of the GLSV II fund's young portfolio of 14 investments."

About Global Life Science Ventures:

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany and Switzerland, GLSV is dedicated to supporting early-stage companies originating from universities, scientific institutions or industry, but also invests in selected later-stage companies, including buy-outs. The group currently advises and manages funds totalling more than €200 million. GLSV has now

financed 28 innovative life science companies, twelve of which have completed an exit through IPO, trade sale or M&A. GLSV has built up a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.

Global Life Science Ventures

Industry-born team – Proven track record – Global perspective

Germany

GLSV GmbH

Von-der-Tann-Str. 3

D – 80539 München

Tel. +49 (0)89 288 151 0

Fax +49 (0)89 288 151 30

www.glsv-vc.com

mailbox@glsv-vc.com

Switzerland

GLSV AG

Postplatz 1, P.O. 626

CH – 6301 Zug

Tel. +41 (0)41 727 19 40

Fax +41 (0)41 727 19 45

For additional information, please contact:

Rochat & Partners

Christophe Lamps/Jonathan Leighton

Tel. +41 22 718 37 46

Fax +41 22 786 54 58

E-mail: clamps@rochat-pr.ch / jonathan@rochat-pr.ch